Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07313852 · ClinicalTrials.gov registry record · Phase 1
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT07313852: Clinical Trial Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07313852 is a Phase 1 study that has not yet begun recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07313852, a Phase 1 study, has not yet begun recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
Interventions
- DRUG Blinatumomab Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07313852
The ClinicalTrials.gov registry entry for NCT07313852 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blinatumomab Injection is the first listed.
NCT07313852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07313852 about?
NCT07313852 is a clinical study titled "A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia". The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
What is the current status of trial NCT07313852?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2026-06. Estimated completion is 2029-01.
What interventions are being tested in trial NCT07313852?
The interventions under investigation include: Blinatumomab Injection (DRUG).
Who is sponsoring clinical trial NCT07313852?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.